Technology area: Biotechnology & Pharmaceuticals
50 pending office actions • 40 art units • 48 examiners • 0 of 50 (0%) have an AI response strategy ready • 38 patents granted in the last 365 days
The Brigham and Women's Hospital Inc. has 53 pending office actions in Biotechnology & Pharmaceuticals. Those matters are assigned to 50 distinct examiners across 40 distinct art units, reflecting a highly distributed prosecution profile with limited repetition at the examiner level.
CHANG, KYUNG SOOK is the busiest examiner, with 3 pending matters. The small size of that assignment relative to the portfolio means that broad docket governance is more important than a single-examiner strategy. Counsel should coordinate technical positions across art units while retaining separate response plans for individual examiners.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 8 (16%) |
| §103 only | 15 (30%) |
| §102 only | 2 (4%) |
| §112 only | 3 (6%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 9 (18%) |
| Multi-statute (no §101) | 11 (22%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 2 | 60.5% | +40.8% |
| KONOPKA, CATHERINE ANNE | 2 | 57.5% | +66.2% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| RUNYAN, SILVANA C | 1 | 82.5% | +17.0% |
| STEPHENS, JACQUELINE F | 1 | 75.6% | +14.9% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| COOPER, JONATHAN EPHRAIM | 1 | 46.4% | +31.8% |
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.6% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19113609 | PECTIN FILMS | RUNYAN, SILVANA C | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | AEDER, SEAN E | 43d overdue |
| 17784631 | CONTROL OF A THERAPEUTIC DELIVERY SYSTEM | HAYES, JONATHAN EDWARD | 9d overdue |
| 17923891 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | REDWOOD, CHRISTOPHER EVAN | 5d |
| 18313931 | AUTOMATED DETECTION AND MANAGEMENT OF VAVLULAR HEART DISEASE USING MACHINE LEARNING | LAGOY, KYRA RAND | 12d |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | JOHNSON, ALLISON MARIE | 14d |
| 17739803 | SYSTEMS, METHODS, AND BIOMATERIALS FOR RADIATION THERAPY | DICKINSON, PAUL W | 56d |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | CHANG, KYUNG SOOK | — |
| 18711241 | NOCICEPTOR-SPECIFIC GENE REGULATORY ELEMENTS FOR THE TREATMENT OF PAIN | KONOPKA, CATHERINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19672116 | KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF | HUYNH, PHUONG N | — |
| 19113609 | PECTIN FILMS | RUNYAN, SILVANA C | — |
| 19108988 | SYSTEMS AND METHODS FOR IMPROVED SURGICAL DRAIN | STEPHENS, JACQUELINE F | — |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | CHANG, KYUNG SOOK | — |
| 18859331 | FLEXIBLE ELECTRONICS FOR ANALYTE DETECTION | COOPER, JONATHAN EPHRAIM | — |
| 18827380 | VERO CELL LINES STABLY EXPRESSING HSV ICP0 PROTEIN | KONOPKA, CATHERINE ANNE | — |
| 18799051 | Elastic Biopolymer and Use as a Tissue Adhesive | ANTHOPOLOS, PETER | — |
| 18834704 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | RAHMAN, MASUDUR | — |
| Art Unit | Apps |
|---|---|
| 3791 | 4 |
| 1632 | 3 |
| 1641 | 2 |
| 1613 | 2 |
| 1635 | 2 |
| 1675 | 2 |
| 1687 | 2 |
| 1616 | 1 |
| 3781 | 1 |
| 1743 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19672116 | KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF | HUYNH, PHUONG N | 1641 | DP | Final Rejection | — | Pending | May 08, 2026 |
| 19113609 | PECTIN FILMS | RUNYAN, SILVANA C | 1616 | §103 | Non-Final OA | — | Pending | Mar 20, 2025 |
| 19108988 | SYSTEMS AND METHODS FOR IMPROVED SURGICAL DRAIN | STEPHENS, JACQUELINE F | 3781 | §103 | Non-Final OA | — | Pending | Mar 05, 2025 |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | CHANG, KYUNG SOOK | 1613 | §103§112 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18869925 | MOLECULARLY CLEAVABLE BIOINK FORMULATION | MERCIER, MELISSA S | 1743 | §102 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18859331 | FLEXIBLE ELECTRONICS FOR ANALYTE DETECTION | COOPER, JONATHAN EPHRAIM | 3791 | §103 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18827380 | VERO CELL LINES STABLY EXPRESSING HSV ICP0 PROTEIN | KONOPKA, CATHERINE ANNE | 1635 | §112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18799051 | Elastic Biopolymer and Use as a Tissue Adhesive | ANTHOPOLOS, PETER | 1611 | §103§112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18834704 | GENERATION OF BROWN ADIPOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | RAHMAN, MASUDUR | 1633 | §103 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18711241 | NOCICEPTOR-SPECIFIC GENE REGULATORY ELEMENTS FOR THE TREATMENT OF PAIN | KONOPKA, CATHERINE ANNE | 1635 | §101§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18633827 | METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER | TRAN, KHOA NHAT | 1632 | §112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18700972 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | CHERNYSHEV, OLGA N | 1675 | §102§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18596376 | SYNTHETIC TISSUE BARRIERS AND USES THEREOF | CHANG, KYUNG SOOK | 1613 | §103§112DP | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18572723 | ADENO-ASSOCIATED VIRAL (AAV) VECTORS FOR TISSUE-TARGETED EXPRESSION OF THERAPEUTIC GENES | STAVROU, CONSTANTINA E | 1632 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18530114 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | MCCOLLUM, ANDREA K | 1674 | §101§112 | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18563276 | SYSTEMS AND METHODS FOR PATIENT TRACKING DURING RADIATION THERAPY | SONG, HOON K | 2884 | §103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18558234 | APPARATUS AND METHOD FOR A BIOMIMETIC HUMAN ALVEOLAR LUNG-ON-A-CHIP MODEL | CARREON, ADRIAN JOHN | 1799 | §103 | Final Rejection | — | Pending | Oct 31, 2023 |
| 18281025 | PROFILING EPIGENETIC AGE IN SINGLE CELLS AND WITH LOW-PASS SEQUENCING DATA | ELKINS, BLAKE HARRISON | 1687 | §101§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18272024 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | PURDY, KYLE A | 1637 | §103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18345981 | FUNCTIONAL UTERINE MANIPULATOR | BACHMAN, LINDSEY MICHELE | 3771 | §112DP | Final Rejection | 73d overdue | Pending | Jun 30, 2023 |
| 18269168 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | OH, TAYLOR V | 1625 | §102§103 | Final Rejection | — | Pending | Jun 22, 2023 |
| 18039777 | SPECTROMETRY SYSTEMS, METHODS, AND APPLICATIONS | EPPERT, LUCY CLARE | 3791 | §103§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18027261 | ROBOTIC ARTIFICIAL INTELLIGENCE NASAL/ORAL/RECTAL ENTERIC TUBE | ABBASI, ABDUL HADI | 3795 | §103 | Final Rejection | — | Pending | Mar 20, 2023 |
| 18088039 | SYSTEMS AND METHODS FOR DETERMINING CARDIAC OUTPUT | TU, AURELIE H | 3791 | §101§102§103§112 | Final Rejection | — | Pending | Dec 23, 2022 |
| 17786121 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF TUBERCULOSIS | DEVI, SARVAMANGALA | 1645 | §112 | Final Rejection | 30d overdue | Pending | Nov 30, 2022 |
| 17928452 | USE OF MICROVESICLE SIGNATURE FOR THE DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION | YU, TIAN NMN | 1681 | §101§103 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 17925180 | OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | 4d overdue | Pending | Nov 14, 2022 |
| 17923891 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103§112 | Final Rejection | 5d | Pending | Nov 07, 2022 |
| 17922661 | SYSTEM AND METHOD FOR ENDO-PHENOTYPING AND RISK STRATFYING OBSTRUCTIVE SLEEP APNEA | MORONESO, JONATHAN DREW | 3791 | §101§103 | Non-Final OA | — | Pending | Nov 01, 2022 |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | AEDER, SEAN E | 1642 | §103§112 | Non-Final OA | 43d overdue | Pending | Oct 12, 2022 |
| 17995058 | Methods, Compositions, and Kits for Identifying Regions of Genomic DNA Bound to a Protein | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | 53d overdue | Pending | Sep 29, 2022 |
| 17913509 | TNFAIP3 AS A BIOMARKER FOR AUTOIMMUNE DISEASES | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | — | Pending | Sep 22, 2022 |
| 17907781 | SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTI-SPECIFIC ANTIBODIES | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 53d | Pending | Aug 29, 2022 |
| 17798937 | METHODS OF MEASURING AND PURIFYING EXTRACELLULAR VESICLES | GERMAIN, ADAM ADRIEN | 1772 | §103 | Final Rejection | — | Pending | Aug 11, 2022 |
| 17797697 | BASE EDITOR PREDICTIVE ALGORITHM AND METHOD OF USE | THOMPSON, MILANA KAYE | 1687 | §103 | Non-Final OA | 34d | Pending | Aug 04, 2022 |
| 17878458 | SYSTEM, ASSAY AND METHOD FOR PARTITIONING PROTEINS | FLINDERS, JEREMY C | 1684 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17784631 | CONTROL OF A THERAPEUTIC DELIVERY SYSTEM | HAYES, JONATHAN EDWARD | 1685 | §102§103§112 | Non-Final OA | 9d overdue | Pending | Jun 11, 2022 |
| 17836972 | RESIDENCE STRUCTURES AND RELATED METHODS | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Final Rejection | — | Pending | Jun 09, 2022 |
| 17780407 | COMPOSITIONS AND METHODS FOR EPITOPE SCANNING | WEN, SHARON X | 1641 | §103 | Non-Final OA | — | Pending | May 26, 2022 |
| 17739803 | SYSTEMS, METHODS, AND BIOMATERIALS FOR RADIATION THERAPY | DICKINSON, PAUL W | 1618 | §102§103§112 | Final Rejection | 56d | Pending | May 09, 2022 |
| 17637145 | MEDICAL MICRODEVICE ANCHORING APPARATUS, INSTALLATION AND RETRIEVAL TOOLS, AND METHODS OF USING SAME | MEDWAY, SCOTT J | 3783 | §102 | Non-Final OA | 33d | Pending | Feb 22, 2022 |
| 17625425 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | MCMILLIAN, KARA RENITA | 1623 | §102§112 | Final Rejection | — | Pending | Jan 07, 2022 |
| 17570104 | FUSION PROTEIN NANODISK COMPOSITIONS AND METHODS OF TREATMENT | MARTIN, RACHEL E | 1657 | §103 | Non-Final OA | 81d overdue | Pending | Jan 06, 2022 |
| 17558402 | Polyphenols as Modulators of Platelet Function | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Dec 21, 2021 |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Final Rejection | 14d | Pending | Oct 01, 2021 |
| 16992362 | THREE-DIMENSIONAL DIFFERENTIATION OF EPIBLAST SPHEROIDS TO KIDNEY ORGANOIDS MODELS STAGE-SPECIFIC EPITHELIAL PHYSIOLOGY, MORPHOGENESIS, AND DISEASE | MOLOYE, TITILAYO | 1632 | Other | Final Rejection | 22d | Pending | Aug 13, 2020 |
| 18911571 | MEDICAL INFORMATION PROCESSING APPARATUS AND COMPUTER-READABLE STORAGE MEDIUM | YANG, JIANXUN | 2662 | §103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18231793 | METHOD FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE RISK VIA ANALYSIS OF IgG GLYCOME | SCHULTZHAUS, JANNA NICOLE | 1796 | §101§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18342646 | REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION | NICOL, ALEXANDER W | 1634 | §112 | Final Rejection | — | Pending | Jun 27, 2023 |
| 18313931 | AUTOMATED DETECTION AND MANAGEMENT OF VAVLULAR HEART DISEASE USING MACHINE LEARNING | LAGOY, KYRA RAND | 3685 | §101§103 | Final Rejection | 12d | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Brigham and Women's Hospital Inc. has 50 pending office actions as of October 2026, spread across 40 art units and 48 examiners.
Kyung Sook Chang has the most, with 2 of The Brigham and Women's Hospital Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
